Show simple item record

dc.contributor.authorBradford, Eric
dc.contributor.authorJacobson, Sean
dc.contributor.authorVarasteh, Jason
dc.contributor.authorComellas, Alejandro P.
dc.contributor.authorWoodruff, Prescott
dc.contributor.authorO’Neal, Wanda
dc.contributor.authorDeMeo, Dawn L.
dc.contributor.authorLi, Xingnan
dc.contributor.authorKim, Victor
dc.contributor.authorCho, Michael
dc.contributor.authorCastaldi, Peter J.
dc.contributor.authorHersh, Craig
dc.contributor.authorSilverman, Edwin K.
dc.contributor.authorCrapo, James D.
dc.contributor.authorKechris, Katerina
dc.contributor.authorBowler, Russell P.
dc.date.accessioned2017-11-17T16:37:04Z
dc.date.available2017-11-17T16:37:04Z
dc.date.issued2017-10-24
dc.identifier.citationThe value of blood cytokines and chemokines in assessing COPD 2017, 18 (1) Respiratory Researchen
dc.identifier.issn1465-993X
dc.identifier.pmid29065892
dc.identifier.doi10.1186/s12931-017-0662-2
dc.identifier.urihttp://hdl.handle.net/10150/626086
dc.description.abstractBackground: Blood biomarkers are increasingly used to stratify high risk chronic obstructive pulmonary disease (COPD) patients; however, there are fewer studies that have investigated multiple biomarkers and replicated in multiple large well-characterized cohorts of susceptible current and former smokers. Methods: We used two MSD multiplex panels to measure 9 cytokines and chemokines in 2123 subjects from COPDGene and 1117 subjects from SPIROMICS. These biomarkers included: interleukin (IL)-2, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, eotaxin/CCL-11, eotaxin-3/CCL-26, and thymus and activation-regulated chemokine (TARC)/CCL-17. Regression models adjusted for clinical covariates were used to determine which biomarkers were associated with the following COPD phenotypes: airflow obstruction (forced expiratory flow at 1 s (FEV1%) and FEV1/forced vital capacity (FEV1/FVC), chronic bronchitis, COPD exacerbations, and emphysema. Biomarker-genotype associations were assessed by genome-wide association of single nucleotide polymorphisms (SNPs). Results: Eotaxin and IL-6 were strongly associated with airflow obstruction and accounted for 3-5% of the measurement variance on top of clinical variables. IL-6 was associated with progressive airflow obstruction over 5 years and both IL-6 and IL-8 were associated with progressive emphysema over 5 years. None of the biomarkers were consistently associated with chronic bronchitis or COPD exacerbations. We identified one novel SNP (rs9302690 SNP) that was associated with CCL17 plasma measurements. Conclusion: When assessing smoking related pulmonary disease, biomarkers of inflammation such as IL-2, IL-6, IL-8, and eotaxin may add additional modest predictive value on top of clinical variables alone.
dc.description.sponsorshipNational Heart, Lung, and Blood Institute [R01 HL129937, R01 HL089897, R01 HL089856]; COPD Foundation; NIH/NHLBI [HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C]en
dc.language.isoenen
dc.publisherBIOMED CENTRAL LTDen
dc.relation.urlhttp://respiratory-research.biomedcentral.com/articles/10.1186/s12931-017-0662-2en
dc.rights© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleThe value of blood cytokines and chemokines in assessing COPDen
dc.typeArticleen
dc.contributor.departmentUniv Arizona, Coll Med, Dept Meden
dc.identifier.journalRespiratory Researchen
dc.description.noteOpen Access Journal.en
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
refterms.dateFOA2018-06-23T07:27:37Z
html.description.abstractBackground: Blood biomarkers are increasingly used to stratify high risk chronic obstructive pulmonary disease (COPD) patients; however, there are fewer studies that have investigated multiple biomarkers and replicated in multiple large well-characterized cohorts of susceptible current and former smokers. Methods: We used two MSD multiplex panels to measure 9 cytokines and chemokines in 2123 subjects from COPDGene and 1117 subjects from SPIROMICS. These biomarkers included: interleukin (IL)-2, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, eotaxin/CCL-11, eotaxin-3/CCL-26, and thymus and activation-regulated chemokine (TARC)/CCL-17. Regression models adjusted for clinical covariates were used to determine which biomarkers were associated with the following COPD phenotypes: airflow obstruction (forced expiratory flow at 1 s (FEV1%) and FEV1/forced vital capacity (FEV1/FVC), chronic bronchitis, COPD exacerbations, and emphysema. Biomarker-genotype associations were assessed by genome-wide association of single nucleotide polymorphisms (SNPs). Results: Eotaxin and IL-6 were strongly associated with airflow obstruction and accounted for 3-5% of the measurement variance on top of clinical variables. IL-6 was associated with progressive airflow obstruction over 5 years and both IL-6 and IL-8 were associated with progressive emphysema over 5 years. None of the biomarkers were consistently associated with chronic bronchitis or COPD exacerbations. We identified one novel SNP (rs9302690 SNP) that was associated with CCL17 plasma measurements. Conclusion: When assessing smoking related pulmonary disease, biomarkers of inflammation such as IL-2, IL-6, IL-8, and eotaxin may add additional modest predictive value on top of clinical variables alone.


Files in this item

Thumbnail
Name:
s12931-017-0662-2.pdf
Size:
1.071Mb
Format:
PDF
Description:
FInal Published Version

This item appears in the following Collection(s)

Show simple item record

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.
Except where otherwise noted, this item's license is described as © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.